Vitamin E protection against chemical-induced cell injury. II. Evidence for a threshold effect of cellular alpha-tocopherol in prevention of adriamycin toxicity

Print
Published on Tuesday, 02 October 2018

Abstract

The cardiomyopathy produced by the widely used anticancer drug adriamycin (ADR) is believed to be related to the production of reaction oxygen species and consumption of reduced glutathione (GSH) during redox cycling of the drug.

Protection by vitamin E against the toxicity of ADR was studied in a model of compromised isolated hepatocytes, generated by physiological alterations in the concentration of cell calcium.

A decrease in cell calcium concentration leads to a greater loss of endogenous alpha-tocopherol and enhances the intracellular hydrolysis of exogenous alpha-tocopheryl esters. With this model, vitamin E (alpha-tocopheryl succinate) at 25 microM protected the calcium-depleted hepatocytes against the toxicity of ADR, in association with greater cellular alpha-tocopherol content as compared to calcium-adequate cells. The incubation of calcium-adequate hepatocytes with increasing concentrations of alpha-tocopheryl succinate up to 200 microM demonstrated that maximal protection by vitamin E was directly dependent on the alpha-tocopherol content of the cells, regardless of the concentration of cell calcium.

The viability of the cells was closely associated with the alpha-tocopherol-mediated maintenance of cellular protein thiols. Viability and protein thiol content of the cells were maximal at cellular alpha-tocopherol levels in the range 0.6-1.0 nmol/10(6) cells in both calcium-depleted and -adequate cells.

It is suggested that the potential use of vitamin E as a protective agent against ADR toxicity in vivo be reevaluated with an emphasis placed on the threshold level of intracellular alpha-tocopherol in the critical target tissue.

 

About this publication.

See also:

- Official Web Site: The Di Bella Method;

- The Di Bella Method (A Fixed Part - Alpha tocopheryl acetate/Vitamin E, approximately 20 grams per day orally);

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives) - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - All-Trans Retinoic Acid, Analogues and/or Derivatives - Approximately 60mg per day orally: 40mg per day Beta-Carotene/β-Carotene, 10mg per day ATRA and 10mg per day Axerophthol palmitate);

- The Di Bella Method (A Fixed Part - Calcium, 2 grams per day, orally);

- The Di Bella Method (A Fixed Part - Cyclophosphamide and/or Hydroxyurea tablets, one or two per day);

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- A case of advanced Multiple Myeloma treated with Di Bella Method (DBM) into total remission for 13 years;

- Neuroblastoma: Complete objective response to biological treatment;

- Oesophageal squamocellular carcinoma: a complete and objective response;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.